Clinical Trials on Glycogen Storage Disease Type 2 in New Zealand
Total 10153 results
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IAUnited States, Brazil, Canada, Denmark, Germany, Italy, Netherlands, Spain
-
Genzyme, a Sanofi CompanyTerminatedGlycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)United States, Taiwan, Germany
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Canada, Australia
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)United States, Netherlands, United Kingdom, Germany
-
BioMarin PharmaceuticalTerminatedPompe DiseaseUnited States, United Kingdom, Australia, France, Germany, New Zealand
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Glycogenosis 2United States
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)United States
-
Genzyme, a Sanofi CompanyRecruitingPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Glycogenesis 2 Acid Maltase DeficiencyCroatia, United States, Italy, Belgium, Czechia
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II)United States, Russian Federation, United Kingdom, Bulgaria, India, Ukraine
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2United States, France, Netherlands
-
Amicus TherapeuticsActive, not recruitingPompe DiseaseUnited States, Netherlands, United Kingdom, Australia, Germany, New Zealand
-
Genzyme, a Sanofi CompanyActive, not recruitingGlycogen Storage Disease Type II-Pompe's DiseaseUnited States, France, Japan, Taiwan, United Kingdom
-
Institute of Liver and Biliary Sciences, IndiaRecruitingGlycogen Storage DiseasesIndia
-
Columbia UniversityWithdrawnGlycogen Storage Disease Type IIUnited States
-
Edgar National Centre for Diabetes ResearchUniversity of OtagoUnknown
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)United States, France, Canada, Netherlands, Australia
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II;Pompe's DiseaseCzechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe Disease Infantile-OnsetUnited States, France, South Africa
-
Insulet CorporationCompleted
-
North Shore Hospital, New ZealandCompletedObesity | Type 2 Diabetes MellitusNew Zealand
-
Amicus TherapeuticsActive, not recruitingPompe Disease (Late-onset)United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
-
University of OtagoEdgar National Centre for Diabetes ResearchCompletedObesity | Type 2 Diabetes MellitusNew Zealand
-
Suzhou Alphamab Co., Ltd.Novotech (Australia) Pty LimitedCompleted
-
Amicus TherapeuticsRecruitingPompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompleted
-
Amicus TherapeuticsCompletedGlycogen Storage Disease Type II | Pompe DiseaseUnited States
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
-
Genzyme, a Sanofi CompanyTerminatedPompe DiseaseUnited States
-
SanofiRecruitingGlycogen Storage Disease Type IIBelgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
-
Amicus TherapeuticsTerminatedLate-onset Pompe DiseaseUnited States, Canada, Australia, Belgium
-
Genzyme, a Sanofi CompanyRecruitingGlycogen Storage Disease Type II | Pompe DiseaseHungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe Patients Untreated or Treated With rhGAASpain, Slovenia, Serbia, Korea, Republic of, Greece, Australia, Singapore, Brazil, Canada, Taiwan, Ireland, Poland, Romania
-
Zhejiang Doer Biologics Co., Ltd.RecruitingHealthy, Obesity, MetabolicallyNew Zealand
-
Bispebjerg HospitalCompleted
-
Christchurch HospitalUnknownDiabetes Mellitus, Type 2New Zealand
-
Syneos HealthUS Specialty Formulations, LLCCompletedSARS-CoV-2 (COVID-19)New Zealand
-
Eli Lilly and CompanyCompletedType 2 DiabetesIndia, Mexico, New Zealand, South Africa
-
Zafgen, Inc.CompletedType 2 Diabetes Mellitus | Overweight and ObesityAustralia, New Zealand
-
Assembly BiosciencesNot yet recruitingRecurrent Genital Herpes Simplex Type 2New Zealand
-
Academy of Nutrition and DieteticsCompletedEnd Stage Renal Disease Requiring HemodialysisNew Zealand
-
Diatranz Otsuka LimitedCompleted
-
Hoffmann-La RocheCompletedEnd Stage Renal DiseaseNew Zealand
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedMucositis | Xerostomia | Radiation Toxicity | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma... and other conditionsUnited States, New Zealand
-
PfizerCompletedType 2 Diabetes PatientsUnited States
-
Rutgers, The State University of New JerseyCompleted
-
PfizerTerminated
-
Christchurch Clinical Studies Trust LtdMedtronicUnknownType1diabetesNew Zealand